-
Daclizumab (trade name Zinbryta) is a
therapeutic humanized monoclonal antibody which was used for the
treatment of
adults with
relapsing forms of multiple...
- the
humanized monoclonal antibody daclizumab, with
Roche under a
license that
called for a 15% royalty.
Daclizumab became the
first humanized monoclonal...
-
spondylitis by
their ability to bind to and
inhibit TNF-α.
Basiliximab and
daclizumab inhibit IL-2 on
activated T
cells and
thereby help
prevent acute rejection...
-
biological half-life of
antibodies is
typically on the
order of days, see
daclizumab and
erenumab by way of example. To
visualize and
quantify the distribution...
- to the graft. Anti-IL-2Rα
receptor antibodies such as
basiliximab and
daclizumab are
increasingly being used in
place of ATG as an
induction therapy, as...
- mouse/human anti-Tac
antibodies in the year 1998:
basiliximab (Simulect) and
daclizumab (Zenapax).
These drugs act by
binding the IL-2a receptor's α chain, preventing...
- (+hyaluronidase)
Ozanimod Ponesimod Siponimod Teriflunomide Other treatments Former Daclizumab Research in
multiple sclerosis Demyelinating diseases Other List of multiple...
-
Immunosuppressive drugs such as the
therapeutic monoclonal antibody daclizumab, ciclosporin,
methotrexate and Adalimumab, sold
under the
trade name Humira...
- (vemurafenib), for late-stage V600E BRAF mutation-positive melanoma.
Zenapax (
daclizumab), for the
prevention of
acute transplant rejection.
Diabetes management...
- receptor. Moreover, for
treatment of
multiple sclerosis, drug
called daclizumab binds to IL2RA and so
blocks high-affinity IL-2
receptors on recently...
